Navigation Links
Key Protein May Lead to Faster Acting Anti-Depression Drugs
Date:3/23/2009

NEW YORK, March 23 /PRNewswire-USNewswire/ -- Research conducted by Nobel laureate Paul Greengard, Medical Director of The Michael Stern Parkinson's Research Center at The Rockefeller University, Dr. Jennifer L. Warner-Schmidt in New York and colleagues in Sweden, demonstrated in the Journal of Neuroscience that the brain protein called p11 could lead pharmaceutical companies to develop anti-depression drugs that begin working within hours or days rather than the weeks or even months required by current drugs.

This study, Role of p11 in Cellular and Behavior Effects of 5-HT4 Receptor Stimulation, solidifies the protein p11 as a key determinant of vulnerability to depression. This new research shows that p11 activates a serotonin receptor in the brain known for producing rapid antidepressant response.

"There is pressing clinical need for faster-acting antidepressants," says Greengard. "An understanding of the cellular mechanisms underlying the therapeutic actions of these drugs may lead to better treatments with fewer side effects." In fact, each year over 17 million American adults experience at least one episode of clinical depression. Depression experts claim that many people with a depressive illness never seek treatment. Perhaps if there were antidepressants available that could start working in hours or days rather than weeks or months, more people would seek treatment.

Previous research by Greengard, who was awarded the 2000 Nobel Prize in Medicine or Physiology, helped establish p11 as an important protein that regulates signaling in the brain by the neurotransmitter serotonin, which has long been linked to mood. Michael Stern Parkinson's Research Center scientists begun studying p11 because the serotonin system which is central to depression is connected to dopamine in Parkinson's disease.

The Michael Stern Parkinson's Research Foundation vision is a world without Parkinson's disease. To accomplish their vision, and cognizant that Parkinson's disease is the world's second most prevalent neurological disease after Alzheimer's, The Michael Stern Parkinson's Research Foundation mission is to fund promising, intensive, scientific and medical research that will delay Parkinson's onset, reduce the severity of its symptoms and provide better treatments, as well as fund research into related neurological diseases that can lead to a Parkinson's cure and, through education of health care professionals and the public, attempt to improve the quality of life of Parkinson's patients and their caregivers and families. www.ParkinsonInfo.org


'/>"/>
SOURCE The Michael Stern Parkinson's Research Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Bone Biologics Announces Significant Milestone for Spinal Fusion Surgery Using Recombinant Protein and Demineralized Bone Matrix
2. Aiming at Multiple Alzheimers Proteins May be Key to Success
3. Protein Shown to Play a Key Role in Normal Development of Nervous System
4. St. Jude Study Gives New Insights Into How Cells Accessorize Their Proteins
5. The First Direct Structural Evidence of SV2A has Been Revealed Thanks to Protein Tomography(TM), and Published in BBRC
6. Protein Key to Control Growth of Blood Cells
7. Phase II Data on Lillys Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with Alzheimers Disease
8. Pressure Cycling Technology (PCT) Results in a Higher Yield of Proteins and in the Extraction of Proteins Not Previously Identified in Cancer, Stroke, and IVF Studies
9. Ion Mobility Diagnostic Test from Quest Diagnostics is First to Provide Direct Physical Measurement of Lipoprotein Particles, Cardiovascular Disease Indicators, Study Finds
10. CellCyte Genetics Corporation Selects Washington University School of Medicine to Perform Study on CellCytes Glycoprotein Products in Heart Attack Disease Model
11. Protein Tomography(TM) Reveals Molecular Mode of Action of Humax-EGFr Published in PNAS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , Deutschland und GERMANTOWN, Maryland ... Zusammenarbeit mit Therawis bedient ... bei Brustkrebs   QIAGEN N.V. (NASDAQ: ... gab heute bekannt, eine Lizenz- und Entwicklungsvereinbarung mit ... Assays für die Onkologie eingegangen zu sein. Ein ...
(Date:5/25/2016)... YORK , May 25, 2016  According to ... reached $381 billion in 2015.  Though these are ... plenty of opportunity for success for companies that ... in search of new growth prospects medical device ... on research and development (R&D) than do companies ...
(Date:5/25/2016)... NORTH CHESTERFIELD, Va. , May 25, 2016 ... commercially-available next-generation sequencing test for wounds and infections. ... fungi, ALL parasites, and select viruses. The test ... infected area. David G. ... advanced molecular testing to facilitate wound healing: "We ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... , ... Aimed at nurses and employees in the health care world, this ... the nursing and health care industry. It also provides insight to the developing trends ... , As the nursing industry is coming out of one of the biggest recessions ...
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media ... Janet Yellen and company to wait until March 2017 for an interest rate increase, ... Mack Robinson College of Business. , “The Federal Open Market Committee (FOMC) dot charts ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cabot Corporation, Pfizer, and ... according to court documents and SEC filings. A jury has returned a ... American Optical Corporation, Case No. BC588866, Los Angeles County, California. The jury awarded ...
(Date:5/26/2016)... ... , ... Connor Sports, through its Connor Cares initiative, will continue ... Catchings Legacy Tour that will commemorate the Indiana Fever legend’s hall-of-fame career and ... forms and levels of the game, Connor Sports has committed to a significantly increased ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cardiac arrhythmia is ... impact on long-term patient survival, reports a team of UPMC researchers in the ... in the Journal of Thoracic and Cardiovascular Surgery, provide critical information that will ...
Breaking Medicine News(10 mins):